CEUS vs. AMRI for Liver Cancer Detection
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to find the best way to detect early-stage liver cancer (HCC) in individuals with uncertain liver nodules. It compares two imaging methods: a special type of MRI (AMRI) and an enhanced ultrasound. Participants should have liver cirrhosis, which causes scarring, and uncertain nodules but no liver cancer at the start of the study. As an unphased trial, this study offers participants the chance to contribute to important research that could enhance early detection methods for liver cancer.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that aMRI and CEUS imaging are safe for early-stage HCC detection?
Previous studies have shown that both abbreviated MRI (aMRI) and contrast-enhanced ultrasound (CEUS) are generally safe for patients. Research indicates that aMRI, with its shorter imaging procedures, is well-tolerated, though some studies suggest it may not be preferred by everyone. In contrast, CEUS has proven extremely safe, even for those unable to use other imaging methods due to allergies or claustrophobia. CEUS produces clear images without significant side effects. Overall, both imaging techniques have a strong safety record, making them reliable options for patients considering study participation.12345
Why are researchers excited about this trial?
Researchers are excited about this trial because it compares two advanced imaging techniques, CEUS and AMRI, for detecting hepatocellular carcinoma (HCC) in patients with unclear liver nodules. Unlike traditional imaging methods, these techniques offer more precise and dynamic liver imaging. CEUS uses ultrasound with contrast to enhance visibility, while AMRI provides detailed magnetic resonance imaging with a focus on liver tissue. By evaluating these methods, researchers aim to improve early and accurate detection of HCC, potentially leading to better patient outcomes and more personalized treatment planning.
What evidence suggests that aMRI and CEUS imaging are effective for early-stage HCC detection?
This trial will compare dynamic contrast-enhanced abbreviated MRI (aMRI) and contrast-enhanced ultrasound (CEUS) for detecting early-stage hepatocellular carcinoma (HCC), a type of liver cancer. Research has shown that both aMRI and CEUS hold promise for this purpose. Studies have found that aMRI surpasses regular ultrasound in identifying and ruling out early signs of HCC, making it more accurate in detecting early cancer. CEUS, meanwhile, boasts a high accuracy rate of 93.7% for diagnosing liver cancers, outperforming some other imaging methods. It excels at detecting changes in blood flow often seen in liver tumors. Both imaging methods are valuable for early detection, which is crucial for effective treatment. Participants in this trial will undergo both aMRI and CEUS imaging at specified intervals to assess their effectiveness in early detection.678910
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging Assessment
Participants undergo both contrast-enhanced ultrasound and abbreviated MRI every 3-6 months to detect early-stage HCC
Follow-up
Participants are monitored for safety and effectiveness after imaging assessments
What Are the Treatments Tested in This Trial?
Interventions
- aMRI imaging
- CEUS imaging
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients with LR3 observations would undergo CEUS and AMRI every 6 months; patients with LR4 observations would undergo CEUS and AMRI 3 months after enrollment and every 6 months thereafter. CEUS and AMRI will preferably be done the same day to minimize burden on the patient, although will be permitted to be completed within 14 days of each other. This interval is sufficiently short to minimize the chance of intervening events. AMRI and CEUS will be performed every 3-6 months until HCC development, regression to LR-1 or LR-2 (i.e., definitely or likely benign, respectively), or end of follow-up at 24 months post-enrollment.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas Southwestern Medical Center
Lead Sponsor
University of Michigan
Collaborator
Citations
Differences between CEUS LI-RADS and CECT ...
The sensitivity of CEUS LR-5 + LR-M for the diagnosis of hepatic malignancies was higher than that of CECT (93.7% vs. 82.7%, p < 0.001). The ...
Research Progress on Contrast-Enhanced Ultrasound ...
CEUS has proven effective in characterizing liver malignancies, detecting metastatic lesions, and monitoring treatment outcomes following local ablation ...
Contrast-Enhanced Ultrasound of Focal Liver Lesions | AJR
The tumor-specific vascularization pattern could be assessed in the majority of cases, and the diagnostic accuracy of CEUS was 83.1% for all benign lesions, ...
4.
insightsimaging.springeropen.com
insightsimaging.springeropen.com/articles/10.1186/s13244-024-01838-xDiagnostic performance of Sonazoid-enhanced CEUS in ...
Among 400 patients with 432 lesions, CEUS showed excellent inter-reader consistency in detecting arterial phase hyperenhancement and Kupffer ...
The Clinical Utility of Liver-Specific Ultrasound Contrast ...
Contrast-enhanced US (CEUS) improves the diagnostic capabilities of an unenhanced US examination, being widely adopted due to its easy access as a complement to ...
Contrast-enhanced ultrasound: a comprehensive review of ...
This article reviews the existing pediatric CEUS literature and provides an overview of safety-related information reported from UCA uses in children.
Retrospective Analysis of the Safety and Cost Implications of ...
The results of our study suggest that CEUS is a safe and cost-effective modality for children. By avoiding further imaging, CEUS contributes to reducing the ...
What is CEUS?
... safety data, show that UCAs are exceedingly safe for the vast majority of patients. The real-time, high resolution images produced by CEUS are often ...
9.
insightsimaging.springeropen.com
insightsimaging.springeropen.com/articles/10.1186/s13244-025-02055-wpregnancy, paediatric, abdominal trauma, complex renal cysts ...
CEUS is extremely safe and can be used in many areas that require repeated high-resolution imaging. Introduction. The introduction of contrast ...
acr–aium–spr–sru practice parameter for the performance of ...
CEUS is often safe for patients with contraindications to CT or MRI, including allergies to iodinated and gadolinium-based contrast material, claustrophobia, or ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.